WINT

Windtree Therapeutics, Inc. is a diversified company. The Company is engaged in the biotechnology business, advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. aPKCi inhibitor platform is a potential high-potency, specific, drug candidate with applications in oncology, particularly in hedgehog pathway-dependent cancers. The Company also has a licensing business model with partnership out-licenses in place. The Company is also focused on environmental services space.